Hypotrichosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Marie Unna hypotrichosis, an autosomal
dominant disorder, exhibits sparse or absent hair at birth. This is followed by
the emergence of coarse, wiry, twisted hair during childhood and eventually
progresses to non-scarring hair loss at puberty. This final stage often follows
a pattern similar to androgenetic alopecia. Affected individuals, regardless of
gender, typically lack scalp hair, eyelashes, and eyebrows from birth. Their
scalp hair transforms into a coarse and wiry texture in early childhood. The
onset of scalp hair loss, resembling the pattern of androgenetic alopecia,
begins around puberty and advances to near-complete baldness. The disorder
results from mutations in U2HR, an inhibitory upstream open reading frame of
the HR gene at 8p21.2. These mutations cause an overactivation of HR, leading
to the condition. Globally, more than 30 affected families and sporadic cases,
totaling around 20 U2HR mutations, have been identified. A Chinese family
revealed a missense mutation in EPS8L3 on chromosome 1p13.2, although this
mutation remains unreported elsewhere. Differential diagnoses encompass
hypotrichosis simplex, loose anagen syndrome, uncombable hair syndrome,
ectodermal dysplasia syndromes, congenital atrichia, androgenetic alopecia, and
alopecia areata. Regrettably, no curative treatment is currently available.
While life expectancy is unaffected, the psychological impact linked to the
hair phenotype can diminish the quality of life for those affected.
Thelansis’s “Hypotrichosis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Hypotrichosis treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Hypotrichosis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Hypotrichosis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment